Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Neogen Corporation (NEOG)

11.82 -0.44 (-3.59%)
At close: October 30 at 4:00:00 PM EDT
11.82 0.00 (0.00%)
After hours: October 30 at 4:00:16 PM EDT
Trade Neogen on Coinbase
Chart Range Bar
Loading chart for NEOG
  • Previous Close 12.26
  • Open 12.15
  • Bid 8.68 x 200
  • Ask 15.01 x 200
  • Day's Range 11.63 - 12.24
  • 52 Week Range 5.37 - 14.26
  • Volume 1,946,838
  • Avg. Volume 3,329,155
  • Market Cap (intraday) 2.58B
  • Beta (5Y Monthly) 1.79
  • PE Ratio (TTM) --
  • EPS (TTM) -0.26
  • Earnings Date Oct 6, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 14.00
  • Zacks Rating Neutral

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis. The company has a strategic collaboration with Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

www.neogen.com

2,636

Full Time Employees

May 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NEOG
69.10%
S&P 500 (^GSPC)
10.73%

1-Year Return

NEOG
97.00%
S&P 500 (^GSPC)
11.11%

3-Year Return

NEOG
21.51%
S&P 500 (^GSPC)
81.91%

5-Year Return

NEOG
72.06%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 222.8M
Earnings -11.9M
Profit Margin -5.34%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
50M
100M
150M
200M
-8.0%
-7.0%
-6.0%

Analyst Insights

View More

Analyst Price Targets

14.00
14.00 Average
11.82 Current
14.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/30/2026
Analyst Guggenheim
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 12 -> 14

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -6.35%

  • Return on Assets (ttm)

    -0.14%

  • Return on Equity (ttm)

    -2.67%

  • Revenue (ttm)

    884M

  • Net Income Avi to Common (ttm)

    -56.1M

  • Diluted EPS (ttm)

    -0.26

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    172M

  • Total Debt/Equity (mrq)

    37.11%

  • Levered Free Cash Flow (ttm)

    38.94M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: